Corrigendum to “Styrene-maleic acid copolymer-encapsulated CORM2, a water-soluble carbon monoxide (CO) donor with a constant CO-releasing property, exhibits therapeutic potential for inflammatory bowel disease” [Journal of Controlled Release 187 (2014) 121] (Styrene-maleic acid copolymer-encapsulated CORM2, a water-soluble carbon monoxide (CO) donor with a constant CO-releasing property, exhibits therapeutic potential for inflammatory bowel disease (2014) 187 (14–21), (S0168365914003216), (10.1016/j.jconrel.2014.05.018));Styrene-maleic acid copolymer-encapsulated CORM2, a water-soluble carbon monoxide (CO) donor with a constant CO-releasing property, exhibits therapeutic potential for inflammatory bowel disease

Journal of Controlled Release

Volumn 187, Issue , 2014, Pages 14-21

  Yin, Hongzhuan ^a   Fang, Jun ^a   Liao, Long ^a   Nakamura, Hideaki ^a   Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

Carbon monoxide; Inflammation; Inflammatory bowel disease; Micelles; Reactive oxygen species; Styrene maleic acid copolymer

Indexed keywords

CARBON MONOXIDE; CELL DEATH; CONTROLLED DRUG DELIVERY; MAMMALS; MICELLES; PHYSIOLOGY; PORPHYRINS; REACTIVE OXYGEN SPECIES; SOLUBILITY; STYRENE; SULFUR COMPOUNDS; TARGETED DRUG DELIVERY;

DEXTRAN SULFATE SODIUM; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY CYTOKINES; MONOCYTE CHEMOTACTIC PROTEIN-1; STYRENE MALEIC ACID COPOLYMER; THERAPEUTIC POTENTIALS; TUMOR NECROSIS FACTOR ALPHA;

DISEASES;

CARBON MONOXIDE; COPOLYMER; DEXTRAN SULFATE; DIMER; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; STYRENE MALEIC ACID; TRICARBONYLDICHLORORUTHENIUM(II); TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CYTOKINE; MALEIC ACID; MALEIC ACID DERIVATIVE; MICELLE; ORGANOMETALLIC COMPOUND; STYRENE; TRICARBONYLDICHLORORUTHENIUM (II) DIMER; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON MUCOSA; COLON ULCER; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG RELEASE; DRUG SYNTHESIS; FEMALE; HISTOPATHOLOGY; HYDRODYNAMICS; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM HEMORRHAGE; ULCERATIVE COLITIS; UPREGULATION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; COLITIS; COLON; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MICELLE; PATHOLOGY; SOLUBILITY; TISSUE DISTRIBUTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARBON MONOXIDE; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; FEMALE; MALEATES; MICE, INBRED BALB C; MICE, INBRED ICR; MICELLES; ORGANOMETALLIC COMPOUNDS; SOLUBILITY; STYRENE; TISSUE DISTRIBUTION; WATER;

EID: 84901751465     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2021.08.006     Document Type: Erratum

References (38)

1. R. Motterlini, and L.E. Otterbein The therapeutic potential of carbon monoxide Nat. Rev. Drug Discov. 9 2010 728 743 10.1038/nrd3228
2. N.G. Abraham, and A. Kappas Pharmacological and clinical aspects of heme oxygenase Pharmacol. Rev. 60 2008 79 127 10.1124/pr.107.07104 (Pubitemid 351439218)
3. P.A. Rodgers, H.J. Vreman, P.A. Dennery, and D.K. Stevenson Sources of carbon monoxide (CO) in biological systems and applications of CO detection technologies Semin. Perinatol. 18 1994 2 10 (Pubitemid 24064618)
4. M.D. Maines Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications FASEB J. 2 1988 2557 2568
5. J. Fang, T. Akaike, and H. Maeda Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment Apoptosis 9 2004 27 35 (Pubitemid 38270426)
6. S. Tanaka, T. Akaike, J. Fang, T. Beppu, M. Ogawa, F. Tamura, Y. Miyamoto, and H. Maeda Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour Br. J. Cancer 88 2003 902 909 (Pubitemid 36520878)
7. J. Fang, H. Qin, T. Seki, H. Nakamura, K. Tsukigawa, T. Shin, and H. Maeda Therapeutic potential of pegylated hemin for reactive oxygen species-related diseases via induction of heme oxygenase-1: results from a rat hepatic ischemia/reperfusion injury model J. Pharmacol. Exp. Ther. 339 2011 779 789 10.1124/jpet.111.185348
8. D.E. Baranano, M. Rao, C.D. Ferris, and S.H. Snyder Biliverdin reductase: a major physiologic cytoprotectant Proc. Natl. Acad. Sci. U. S. A. 99 2002 16093 16098 (Pubitemid 35462754)
9. Y. Wei, P. Chen, M. de Bruyn, W. Zhang, E. Bremer, and W. Helfrich Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats BMC Gastroenterol. 10 2010 42 10.1186/1471-230X-10-42
10. T. Takagi, Y. Naito, K. Uchiyama, T. Suzuki, I. Hirata, K. Mizushima, H. Tsuboi, N. Hayashi, O. Handa, T. Ishikawa, N. Yagi, S. Kokura, H. Ichikawa, and T. Yoshikawa Carbon monoxide liberated from carbon monoxide-releasing molecule exerts an anti-inflammatory effect on dextran sulfate sodium-induced colitis in mice Dig. Dis. Sci. 56 2011 1663 1671 10.1007/s10620-010-1484-y
11. R. Motterlini Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, anti-ischaemic and anti-inflammatory activities Biochem. Soc. Trans. 35 2007 1142 1146 (Pubitemid 350214248)
12. H. Maeda Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 88 2012 53 71
13. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
14. H. Maeda Macromolecular therapeutics in cancer treatment: the EPR effect and beyond J. Control. Release 164 2012 138 144 10.1016/j.jconrel.2012.04.038
15. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151 10.1016/j.addr.2010.04.009
16. D.C. Baumgart, and S.R. Carding Inflammatory bowel disease: cause and immunobiology Lancet 369 2007 1627 1640 (Pubitemid 46722636)
17. B. Khor, A. Gardet, and R.J. Xavier Genetics and pathogenesis of inflammatory bowel disease Nature 474 2011 307 317 10.1038/nature10209
18. T. Ohkusa, T. Nomura, and N. Sato The role of bacterial infection in the pathogenesis of inflammatory bowel disease Intern. Med. 43 2004 534 539 (Pubitemid 39206689)
19. J.C. Arthur, E. Perez-Chanona, M. Mühlbauer, S. Tomkovich, J.M. Uronis, T.J. Fan, B.J. Campbell, T. Abujamel, B. Dogan, A.B. Rogers, J.M. Rhodes, A. Stintzi, K.W. Simpson, J.J. Hansen, T.O. Keku, A.A. Fodor, and C. Jobin Intestinal inflammation targets cancer-inducing activity of the microbiota Science 338 2012 120 123 10.1126/science.1224820
20. A. Rezaie, R.D. Parker, and M. Abdollahi Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig. Dis. Sci. 52 2007 2015 2021 (Pubitemid 47246507)
21. K.P. Pavlick, F.S. Laroux, J. Fuseler, R.E. Wolf, L. Gray, J. Hoffman, and M.B. Grisham Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease Free Radic. Biol. Med. 33 2002 311 322 (Pubitemid 34786271)
22. A.K. Iyer, K. Greish, J. Fang, R. Murakami, and H. Maeda High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor Biomaterials 28 2007 1871 1881 (Pubitemid 46123550)
23. A.M. Sundin, and J.E. Larsson Rapid and sensitive method for the analysis of carbon monoxide in blood using gas chromatography with flame ionisation detection J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 766 2002 115 121 (Pubitemid 34142382)
24. S. Wirtz, C. Neufert, B. Weigmann, and M.F. Neurath Chemically induced mouse models of intestinal inflammation Nat. Protoc. 2 2007 541 546 (Pubitemid 47040018)
25. K. Greish, T. Sawa, J. Fang, T. Akaike, and H. Maeda SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours J. Control. Release 97 2004 219 230 (Pubitemid 38759479)
26. R. Duncan Polymer therapeutics as nanomedicines: new perspectives Curr. Opin. Biotechnol. 22 2011 492 501 10.1016/j.copbio.2011.05.507
27. R. Duncan, and M.J. Vicent Polymer therapeutics - prospects for 21st century: the end of the beginning Adv. Drug Deliv. Rev. 65 2013 60 70 10.1016/j.addr.2012.08.012
28. J. Cassidy, D.R. Newell, S.R. Wedge, and J. Cummings Pharmacokinetics of high molecular weight agents Cancer Surv. 17 1993 315 341
29. N. Nishiyama, and K. Kataoka Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery Pharmacol. Ther. 112 2006 630 648 (Pubitemid 44592613)
30. H. Nakamura, J. Fang, B. Gahininath, K. Tsukigawa, and H. Maeda Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles J. Control. Release 155 2011 367 375 10.1016/j.jconrel.2011.04.025
31. R. Motterlini, and L.E. Otterbein The therapeutic potential of carbon monoxide Nat. Rev. Drug Discov. 9 2010 728 743 10.1038/nrd3228
32. L.E. Otterbein, F.H. Bach, J. Alam, M. Soares, H. Tao Lu, M. Wysk, R.J. Davis, R.A. Flavell, and A.M. Choi Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway Nat. Med. 6 2000 422 428 (Pubitemid 30208159)
33. P. Sawle, R. Foresti, B.E. Mann, T.R. Johnson, C.J. Green, and R. Motterlini Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages Br. J. Pharmacol. 145 2005 800 810 (Pubitemid 41076287)
34. M.G. Bani-Hani, D. Greenstein, B.E. Mann, C.J. Green, and R. Motterlini Modulation of thrombin-induced neuroinflammation in BV-2 microglia by carbon monoxide-releasing molecule 3 J. Pharmacol. Exp. Ther. 318 2006 1315 1322 (Pubitemid 44268341)
35. K. Tsoyi, Y.M. Ha, Y.M. Kim, Y.S. Lee, H.J. Kim, H.J. Kim, H.G. Seo, J.H. Lee, and K.C. Chang Activation of PPAR-γ by carbon monoxide from CORM-2 leads to the inhibition of iNOS but not COX-2 expression in LPS-stimulated macrophages Inflammation 32 2009 364 371 10.1007/s10753-009-9144-0
36. C. Nathan Neutrophils and immunity: challenges and opportunities Nat. Rev. Immunol. 6 2006 173 182 (Pubitemid 43290987)
37. D.M. Mosser, and J.P. Edwards Exploring the full spectrum of macrophage activation Nat. Rev. Immunol. 8 2008 958 969 10.1038/nri2448
38. A.C. Bulua, A. Simon, R. Maddipati, M. Pelletier, H. Park, K.Y. Kim, M.N. Sack, D.L. Kastner, and R.M. Siegel Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS) J. Exp. Med. 208 2011 519 533 10.1084/jem.20102049